FIELD: pharmaceuticals.
SUBSTANCE: invention relates to compounds of formula (I) or (Ia) that inhibit the enzymatic tyrosine kinase activity of a protein selected from the Abelson protein (ABL1), Abelson-related protein (ABL2) or the BCR-ABL1 chimeric protein, compositions thereof, methods of inhibiting the enzymatic tyrosine kinase activity of the protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or BCR-ABL1 chimeric protein, and methods of treating diseases in which modulation of BCR-ABL1 activity prevents, suppresses, or alleviates the pathology and/or symptomatology of the disease.
EFFECT: obtaining of new compounds with inhibitory enzymatic tyrosine kinase activity of a protein selected from the Abelson protein (ABL1), Abelson-related protein (ABL2) or the BCR-ABL1 chimeric protein.
24 cl, 2 tbl, 232 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANILIDES OF AMINO ACIDS AS LOW-MOLECULAR MODULATORS IL-17 | 2019 |
|
RU2815505C2 |
| SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE FOR TREATMENT OF PATHOLOGICAL CONDITIONS | 2017 |
|
RU2773333C2 |
| INHIBITOR COMPOUNDS | 2013 |
|
RU2673079C2 |
| COMPOUNDS AND METHODS FOR ENHANCING DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES, USING E3 UBIQUITIN LIGASE | 2013 |
|
RU2781452C2 |
| COMPOUNDS AND METHODS FOR ENHANCED DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE | 2013 |
|
RU2666530C2 |
| PYRAZOLPYRIMIDINE COMPOUNDS JAK INHIBITORS AND METHODS | 2009 |
|
RU2539568C2 |
| ION CHANNEL INHIBITORS, PHARMACEUTICAL FORMULATIONS AND APPLICATIONS | 2016 |
|
RU2746188C2 |
| COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY | 2015 |
|
RU2767460C2 |
| HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | 2012 |
|
RU2648997C2 |
| THIENO[2,3-c]QUINOLIN-4-ONE DERIVATIVES, USEFUL IN TREATMENT OF ERK-DEPENDENT DISEASE | 2011 |
|
RU2574398C2 |
